Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ACADIA Pharmaceuticals Inc Market Cap
Based on ratings from 10 stock analysts, the ACADIA Pharmaceuticals Inc stock price is expected to increase by 67.42% in 12 months. This is calculated by using the average 12-month stock price forecast for ACADIA Pharmaceuticals Inc. The lowest target is $12 and the highest is $39. Please note analyst price targets are not guaranteed and could be missed completely.
ACAD is a stock in Healthcare which has been forecasted to be worth $25.28 as an average. On the higher end, the forecast price is $39 USD by Jason Butler from JMP Securities and on the lower end ACAD is forecasted to be $12 by Salveen Richter from Goldman Sachs.
These are the latest 20 analyst ratings of ACAD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ashwani Verma UBS | Buy | $23 | Maintains | Aug 8, 2024 |
| David Hoang Citigroup | Buy | $23 | Maintains | Aug 8, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $27 | Reiterates | Aug 8, 2024 |
| Gregory Renza RBC Capital | Outperform | $26 | Maintains | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $28 | Maintains | Aug 7, 2024 |
| Jeffrey Hung Morgan Stanley | Equal-Weight | $20 | Downgrade | Aug 7, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $28 | Maintains | Aug 7, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $28 | Maintains | Jul 12, 2024 |
| Keith Tapper BMO Capital | Outperform | $31 | Initiates | Jun 27, 2024 |
| Gregory Renza RBC Capital | Outperform | $29 | Reiterates | Jun 25, 2024 |
| Tazeen Ahmad B of A Securities | Neutral | $22 | Maintains | May 10, 2024 |
| Ami Fadia Needham | Buy | $30 | Reiterates | May 9, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $37 | Reiterates | May 9, 2024 |
| David Hoang Citigroup | Buy | $30 | Maintains | May 9, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $27 | Maintains | May 9, 2024 |
| Paul Matteis Stifel | Hold | $21 | Maintains | May 9, 2024 |
| Joel Beatty Baird | Outperform | $28 | Maintains | May 9, 2024 |
| Uy Ear Mizuho | Neutral | $21 | Maintains | May 9, 2024 |
| Jay Olson Oppenheimer | Perform | $19 | Maintains | May 6, 2024 |
UBS | Buy | Maintains | Apr 30, 2024 |
When did it IPO
2004
Staff Count
630
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Stephen R. Davis J.D.
Market Cap
$2.50B
In 2023, ACAD generated $726.4M in revenue, which was a increase of 40.45% from the previous year. This can be seen as a signal that ACAD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Acadia Pharmaceuticals granted CEO Catherine Owen Adams a one-time equity award of 353,261 stock options at $16.29 each, vesting over four years.
Why It Matters - The equity award for Acadia's new CEO aligns her interests with shareholders, potentially driving stock performance and signaling confidence in the company’s future strategy.
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Acadia Pharmaceuticals has appointed Catherine Owen Adams as CEO, succeeding Steve Davis. She also joins the Board of Directors, bringing a strong track record in the pharmaceutical industry.
Why It Matters - Leadership changes can signal shifts in strategy or company direction, impacting investor confidence and stock performance. Adams' track record may influence future growth prospects for Acadia Pharmaceuticals.
Thu, 19 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Axcelead Drug Discovery Partners has signed a Master Service Agreement with Acadia Pharmaceuticals for drug discovery projects.
Why It Matters - The agreement signals potential revenue growth for Axcelead and validates its capabilities in drug discovery, which may positively influence its stock performance and investor confidence.
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Acadia (ACAD) reported earnings 30 days ago; investors should monitor market reactions and upcoming financial updates for potential stock movements.
Why It Matters - The timing suggests potential market volatility as investors react to earnings performance and anticipate future guidance, impacting stock valuation and sentiment.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Acadia Pharmaceuticals will present at the Morgan Stanley Global Healthcare Conference on Sept 4, 2024, and the Baird Global Healthcare Conference on Sept 11, 2024. Live webcasts available online.
Why It Matters - Acadia Pharmaceuticals' participation in major investor conferences signals potential growth opportunities and increased visibility, which can influence investor sentiment and stock performance.
Mon, 26 Aug 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Acadia's shares declined due to Daybue's weak sales and Nuplazid's phase 3 trial failure. Full-year guidance was cut as new patient acquisition slows, but future performance may improve.
Why It Matters - Declining shares of Acadia reflect concerns over Daybue's sales and Nuplazid's trial failure. Reduced guidance indicates challenges in new patient acquisition, but potential recovery ahead could impact stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
